Masimo (NASDAQ: MASI) has announced that Radius Tº, a wearable, wireless thermometer, has received FDA 510(k) clearance for both prescription and over-the-counter (OTC) use on patients and consumers five years and older.
With continuous temperature measurements and Bluetooth connectivity, Radius Tº automates remote, ongoing body temperature status for clinicians through its paired connection to a Masimo patient monitoring or telehealth solution and for consumers through the Masimo Radius Tº smartphone application.
For prescription use, Radius Tº is compatible with both the Root Patient Monitoring and Connectivity Hub and the Rad-97 patient monitor for use in the hospital, as part of the Masimo Hospital Automation platform.
Price Action: MASI shares are down 1.27% at $237 during the market session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.